Most importantly, those studies showed that the stimulation of NK cell anti-tumor cytotoxicity by chemotherapy could be supported by PD-1/PD-L1 inhibition with anti-PD-1 antibody treatment in NPC patients [137,138]. Here, PDCD1 is linked to neoplasm.